Panacea Biotec’s lenders has approved a one-time settlement plan to clear outstanding dues. All consortium lenders have approved the bilateral one-time settlement (OTS) at 65% of their outstanding debts.
The settlement has been done to resolve the current debt position of the company.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and biotechnology companies in India.
